Evaluation of nanocarrier-based drug delivery systems for targeted cancer therapy: formulation, characterization, and in vitro efficacy

Project Abstract

The present study aims to develop and evaluate nanocarrier-based drug delivery systems for targeted cancer therapy, emphasizing formulation, comprehensive physicochemical characterization, and in vitro efficacy against selected cancer cell lines. Biocompatible and biodegradable nanocarriers, including polymeric nanoparticles and lipid-based nanoparticles, were synthesized using solvent evaporation and nanoprecipitation methods, optimizing particle size, polydispersity index, zeta potential, drug loading, and encapsulation efficiency to achieve favorable pharmacokinetic and pharmacodynamic profiles. Surface functionalization with tumor-targeting ligands (e.g., folic acid and transferrin) was employed to enhance selective uptake by cancer cells overexpressing corresponding receptors, thereby improving therapeutic index and mitigating off-target toxicity. A model chemotherapeutic agent with known hydrophobicity was chosen to investigate encapsulation efficiency, sustained release kinetics, and stability under physiological conditions. Characterization included transmission electron microscopy for morphology, dynamic light scattering for size distribution, differential scanning calorimetry and Fourier-transform infrared spectroscopy for physicochemical interactions, and in vitro release studies under sink conditions to determine burst release and zero-/first-order kinetic regimes. In vitro cellular studies encompassed cytotoxicity assays (MTT/WST-1), cellular uptake quantification via flow cytometry and confocal microscopy, and apoptosis analysis through Annexin V/PI staining and caspase activity measurements across multiple human cancer cell lines representing solid tumors. The targeting efficiency was evaluated by comparing receptor-positive and receptor-negative cell lines, and competitive inhibition assays were performed to confirm receptor-mediated endocytosis. Additionally, intracellular trafficking and endosomal escape were assessed to elucidate the mechanism by which nanocarriers release the drug within the cytoplasm. The study also investigates the impact of nanoparticle characteristics—size, surface charge, and ligand density—on pharmacodynamics and toxicity profiles in a panel of normal cell lines to determine selectivity indices. Data were analyzed using appropriate statistical models to determine significance and reproducibility of results, with correlation analyses performed to relate physicochemical properties to biological outcomes. A stability study under accelerated conditions was conducted to predict shelf-life and storage requirements. The ultimate objective is to establish a robust nanocarrier formulation that demonstrates enhanced cellular uptake, controlled drug release, improved cytotoxicity against cancer cells, and a favorable safety margin in vitro, laying the groundwork for subsequent in vivo validation and translational potential. This work contributes to the growing body of evidence supporting targeted nanomedicine approaches as viable strategies to overcome multidrug resistance and reduce systemic toxicity in cancer therapy.

Project Overview

What This Project Is About

---

A plain-language overview of the topic and what the project investigates.

---

---

The Problem It Addresses

---

Explains a gap in how cancer drugs are delivered to tumors, aiming to reduce side effects and improve effectiveness by using carriers that guide drugs to cancer cells.

---

---

Objectives of the Project

---

1. Understand what nanocarriers are and why they are used in cancer therapy.
2. Learn how to formulate a simple nanocarrier system for a chosen drug.
3. Characterize the physical properties of the formulated nanocarriers (size, charge, stability).
4. Assess basic in vitro efficacy against cancer cell lines in a safe, supervised setting.
5. Discuss how targeting and release profiles may affect treatment outcomes.

---

---

What You Will Do Step by Step

---

1. Review basic literature on nanocarriers and targeted therapy.
2. Choose a model drug and a suitable nanocarrier approach.
3. Prepare the nanocarrier formulation using a simple, reproducible method.
4. Characterize size, surface charge, and stability of the formulation.
5. Test in vitro drug release under simple simulated conditions.
6. Conduct basic cellular uptake or cytotoxicity assays with a cancer cell line.
7. Analyze data to compare with conventional delivery.
8. Summarize findings and discuss potential improvements and limitations.

---

---

Expected Outcome

Gains in understanding of how nanocarriers can improve drug delivery to tumors, with basic data on stability, release, and preliminary efficacy that support further study.